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Highlights 
 There is a high probability that depression screening for asylum-seekers is cost-
effective. 
 The modelling approach produces consistent results despite data uncertainty. 
 Process parameters are particularly important in determining cost-effectiveness. 
 There is considerable monetary value in conducting further research in this area 
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Abstract 
Background: Asylum seekers have a high burden of mental illness owing to traumatic 
experiences before, during and after flight. Screening has been suggested to identify asylum 
seekers with psychosocial needs. However, little is known about the costs of screening 
relative to expected gains. We assessed the cost-effectiveness of population-based 
screening for depression in German asylum reception centres compared to case-finding by 
self-referral. 
 
Methods: Explorative modelling study using a decision tree over 15 months to estimate the 
incremental cost per Quality-Adjusted Life-Year gained. Data points were taken from the 
published literature. Deterministic and probabilistic sensitivity analyses were used to address 
uncertainty around parameter estimates. Value of information analyses were performed to 
indicate the value of future research.  
 
Results: The model demonstrates a high probability (p=83%) of the screening intervention 
being cost-effective at a €50,000/QALY threshold. Cost-utility depends on the process of 
care following screening: when acceptability and adherence parameters were decreased by 
40%, the resulting ICER increased by 27-131%. Eliminating uncertainty was most valuable 
for the screening process and cost parameters, at €3·0 and €4·4 million respectively. 
 
Conclusions: Screening asylum seekers for depression may be a cost-effective strategy to 
identify those in need of care. However, there is considerable value in conducting further 
research in this area, especially regarding resource requirements and the process of care 
following screening. 
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1. Introduction 
The recent period of migration to Europe from conflict areas in the Middle East and East 
Africa poses several political, social and organisational challenges to national governments, 
one of which is how best to organise essential health care services for those whose 
residence status is not yet assured. 
 
One crucial aspect is responding to the high psychosocial needs of this population. The 
burden of mental illness in asylum seekers and refugees is higher than in the general 
population [1,2], owing to pre-, peri- and post-flight factors [3]. National governments have a 
legal obligation under the EU directive on the reception of refugees to protect vulnerable 
individuals, including people with severe psychological illness or those who have 
experienced violence, torture or abuse [4]. However, both the identification and treatment of 
asylum seekers who require psychosocial support remains a challenge, owing to cultural, 
structural, linguistic, financial and organisational barriers [5].  
 
A reception strategy that includes mental health screening and subsequent needs-based 
treatment could help identify refugees in need of psychosocial support. The use of screening 
tools could ensure identification of need if implemented in a standardised manner, improving 
equity and efficiency of the system as well as reducing the burden of disease. It is estimated 
that approximately 11/19 of EU governments have made some provisions for mental health 
screening of refugees [6]. However, there is currently very little evidence on the 
effectiveness and efficiency of such an intervention. Several systematic reviews [7–9] have 
shown that there is no evidence to support mental health screening in the general 
population, but that it may be an effective strategy in high-risk groups with a high disease 
prevalence. 
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A rapid review undertaken by the authors identified only six studies reporting a screening 
programme for depression in asylum seekers or refugees [10–15], none of which examined 
effectiveness or efficacy of the intervention. In the absence of conclusive empirical evidence 
on the entirety of the screening intervention, this study uses a modelling approach to 
consider the cost-effectiveness of this strategy using published data on the different 
elements of the screening pathway. Using a modelling approach with value of information 
analyses allows us to assess the strength of evidence attached to each element and aid 
priority setting for future research in this area.  
2. Material and Methods 
This study uses the German context to model the cost-effectiveness of a depression 
screening intervention for asylum seekers. Germany has seen a large increase in the 
numbers of individuals seeking asylum in recent years, peaking at 745 545 asylum 
applications in 2016 and declining to 185 853 applications in 2018 [16]. Main countries of 
origin in 2018 were Syria, Iraq, Iran, Nigeria and Turkey [16]. In Germany, regional 
authorities are responsible for the health care provision of asylum seekers. Entitlements to 
health care are restricted to acute and painful conditions during the first 15 months after 
arrival and mental health care is only covered on a case-by-case basis [17]. Mental health 
screening is not a routine part of the initial medical examinations in Germany [18]. Instead, 
identification of mental illness is widely based on self-referrals and follow-up care varies 
across the country [19].  
 
We developed a hypothetical population-based screening intervention, analogous to the 
process followed in “stepped care” models of depression treatment [20], provided as an 
optional offer during the initial medical examination in reception centres. Screening for 
depression is carried out on a voluntary basis using a self-complete version of the nine-item 
version of the Patient Health Questionnaire (PHQ9) [20] in the base-case scenario. 
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Assessment of results is carried out by a nurse, who refers anyone with a score above 10, 
suggesting moderate to severe depression, on for a diagnostic appointment. The diagnostic 
appointment is carried out by a psychologist using the Structured Clinical Interview for DSM-
IV (SCID) [21]. Patients who are subsequently diagnosed with moderate to severe 
depression are referred on for 12 sessions of cognitive behavioural therapy (CBT). 
 
[insert figure 1] 
 
2.1. Model Structure and comparators 
We used a decision tree (figure 1) to compare the population-based screening intervention 
for depression to case-finding via self-referrals and follow-up care by non-profit psychosocial 
centres.  The decision tree takes a 15-month time horizon. Screening is followed by three 
months of treatment (12 sessions of cognitive behavioural therapy (CBT)) and 12 months of 
follow-up. This is the length of time for which most accurate estimates of effect size are 
available [22]. Benefits and costs are calculated from a healthcare perspective as the 
responsibility for healthcare provision for asylum seekers in Germany, including the initial 
medical examination, lies entirely with regional healthcare authorities.  
 
Benefits are calculated by adjusting the time spent in each of the three health outcomes 
(“not depressed”, “moderate depression”, “full remission”) over the 12 months of follow-up by 
their respective utility values to calculate quality-adjusted life-years (QALYs). We assume 
that rates of remission are equally distributed over the follow-up period. Costs and benefits 
of the two arms are compared using an incremental cost-effectiveness ratio (ICER). Given 
that there is no recommended cost-effectiveness threshold in Germany, this study uses the 
frequently cited arbitrary threshold of €50,000/QALY to assess cost-effectiveness [23]. Costs 
and benefits are not discounted given the short timeframe. Both the screening and the case 
finding option were also compared with a “do nothing” option, in which no treatment was 
offered to individuals with depression. 
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Microsoft Excel© version 15 was used to build the model and carry out deterministic, 
probabilistic and value of information analyses. 
 
2.2. Study population 
We considered the hypothetical population entering the model as a cohort of 1000 newly 
registered asylum seekers 18 years of age or above. Using data from the most recent 
systematic review, it was estimated that on arrival to Germany, 30·8% of asylum seekers 
suffer from moderate or severe depression [2] as defined in the International Classification of 
Disease (ICD10). 
 
2.3. Sources of Data Points 
All parameter estimates can be found in table 1. 
 
Current practice pathway 
Estimates for regular case-finding are taken from data published by non-profit psychosocial 
centres across Germany, which provide the majority of care for this population [17]. We use 
the number of individuals in treatment and on waiting lists to approximate the current 
demand for services. 
 
Individuals with depression who do not receive treatment may still show improved symptoms 
after 12 months of follow up. We used a 53% spontaneous remission rate elicited from a 
meta-analysis on major depression [24]. 
 
Screening pathway 
Data from existing mental health screening studies in asylum seekers and refugees are used 
to estimate the follow-up after a screening test and the proportion accepting treatment 
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following a diagnosis [11–14]. Mean values are used in instances with diverging values 
across studies.  
 
[insert table 1] 
The rate of screening coverage could not be elicited from existing data. As the hypothetical 
intervention runs alongside the initial health examinations, coverage is expected to be high. 
Nevertheless, implementation gaps may arise and thus a 90% coverage rate is estimated.  
 
Treatment effectiveness & completion 
For the purposes of this paper, treatment of depression with CBT is assumed, as good 
estimates for effectiveness are available for this therapeutic approach. However, results are 
likely to be similar for the other licensed treatments [22]. We use data on treatment 
effectiveness from studies of the general population, as synthesized in a large, international 
meta-analysis [22].  
 
Health-related quality of life 
To estimate utility values for “depression in full remission” and “moderate depression” health 
outcomes, a Euroqol Five Dimensions Questionnaire (EQ5D) valuation from the Dutch 
population [25] is used to approximate German values. The utility value for healthy patients 
was taken from the UK catalogue of utility values for 20–29 year olds [26], corresponding to 
the mean age of asylum seekers in Germany. 
 
Cost data 
Resource requirements of the screening process are based on estimates made by 
Valenstein and colleagues [27]. The nurses’ time required per individual is expanded to ten 
minutes to allow for additional coordinating capacity. Figures in table 1 correspond to the 
German public services salary levels for an upper-band junior nurse and an upper-band 
junior doctor. 
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Costs of the diagnostic interview and treatment are calculated using the tariffs of the 
National Association of Statutory Health Insurance Physicians [28]. Costs of the diagnostic 
interview are calculated using time requirements of the SCID. Costs of treatment are 
calculated for 12 sessions of CBT, with each session is estimated to last 50 minutes. 
 
The annual cost of depression is estimated using a costing study in the general population in 
Germany [29]. Due to the barriers of asylum seekers to accessing regular primary care, only 
inpatient costs, assumed to relate to acute cases of depression and emergency care, are 
considered. The reported average costs per depressed patient are adjusted to reflect 2017 
prices. 
 
2.4. Sensitivity Analysis 
One-way deterministic sensitivity analyses (DSA) are carried out to test the robustness of 
the model by increasing or decreasing each parameter by 40% in turn (table 1). Since utility 
values of health outcomes cannot be assumed to be independent, all three parameters were 
jointly increased or decreased by 40% in a multi-way DSA. 
 
Structural uncertainty is addressed using three multi-way deterministic sensitivity analyses. 
This included varying the screening instrument, mode of diagnostic interview and changing 
the type of therapeutic intervention, changing both effectiveness and resource requirements 
for these elements of the screening pathway (table 2). 
 
[insert table 2] 
 
A probabilistic sensitivity analysis (PSA) was carried out for all parameters, save therapeutic 
costs which are fixed tariffs set by the National Association of Statutory Health Insurance 
Physicians. PSA was conducted using the Monte Carlo method with 1000 simulations, with 
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data points assumed to be independent. For parameters taken from the literature, standard 
errors were taken from publications. Probability and utility parameters were assigned beta 
distributions, treatment effectiveness was assigned a lognormal distribution and the cost of 
depression was assigned a gamma distribution. For parameters which have been estimated 
(pathway parameters, time requirements, staff costs), no assumptions could be made about 
the distribution of uncertainty around these values. Instead, values were increased or 
decreased by 40% to represent maximum and minimum values and a uniform distribution 
was assigned as suggested by Bilcke and colleagues [30]. A large variation of 40% was 
chosen due to the substantial uncertainty that exists around these estimates.  
 
2.5. Value of Information 
The Expected Value of Perfect Information (EVPI) per patient was calculated from PSA 
simulations, by comparing the marginal monetary value obtained under conditions of data 
uncertainty to that obtained under conditions of absolute data certainty [31]. Population EVPI 
was calculated by assuming an annual asylum seeking population of 200,000 per year over 
the course of 5 years, discounted at 3% per year. The short timeframe was chosen due to 
the unpredictability of the size and the instability of the characteristics of this population. 
 
The Expected Value of Perfect Parameter Information (EVPPI) was calculated with an outer 
loop of 1000 iterations and an inner loop of 1000 iterations. Parameters were grouped by 
type (table 3). 
 
Further details on data points, assumptions and methods are provided in the supplementary 
web appendix (see Additional file 1). 
 
[insert table 3] 
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3. Results 
3.1. Base Case Scenario 
In the base case scenario, the option to “do nothing”, leaving all cases of depression 
untreated, generated a total of 801·11 QALYs at a total cost of €47,334 for every 1000 
asylum seekers entering the German healthcare system (table 4). Case-finding for 
depression in asylum seekers generated 803·63 QALYs at a cost of €78,982. The screening 
intervention itself came at a cost of €2·75 per individual screened. Carrying out this 
intervention resulted in 806·58 QALYs generated at a total cost of €137,398 once the costs 
of diagnosis, treatment and the cost of depression to the health system had been taken into 
account (table 4).  
 
Despite being the cheapest option, doing nothing was less cost-effective than case-finding, 
with an incremental cost-effectiveness ratio of €12,588. Compared to case-finding, 
screening resulted in an additional 16 depressed patients in remission after 15 months. This 
translated into 2·95 QALYs at a cost of €58,416 and an ICER of €19,779/QALY (table 4). 
 
[insert table 4] 
 
3.2. Deterministic Sensitivity Analysis 
The DSA revealed that the largest changes in the ICER are seen for screening pathway 
parameters (proportion of patients accepting the therapy offer, proportion completing 
treatment, proportion attending the diagnostic interview and screening coverage), health 
outcome utility values as well as the sensitivity and specificity of the screening instrument 
(figure 2). 
 
None of the structural sensitivity analyses push the ICER above the €50,000/QALY 
threshold (table 4). Changing the screening instrument to Hospital Anxiety and Depression 
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Scale (HADS-D) or the two-item version of the Patient Health Questionnaire (PHQ2) and 
changing the intervention type to Brief CBT do not have a large impact. However, using the 
Mini Neuropathic Psychiatric Interview (MINI) as a diagnostic tool has considerable negative 
impacts on the resulting ICER (€27,263/QALY), as the comparatively worse psychometric 
properties of this tool are not balanced by the resource savings. 
 
[insert figure 2] 
 
3.3. Probabilistic Sensitivity Analysis 
The distribution of matched pairs of the probabilistic analysis illustrated in the cost-
effectiveness plane shows that the screening intervention generally generates more QALYs 
at a higher cost when compared to regular case-finding ( figure 3). The cost-effectiveness 
acceptability curve (CEAC) in figure 4 shows that regular case-finding has a higher 
probability of being cost-effective until a threshold of €25,000/QALY. At a threshold of 
€50,000, the probability of screening being cost-effective is p=83%.  
 
[insert figures 3&4] 
 
3.4. Expected Value of Perfect Information & Expected Value of Perfect Parameter 
Information 
The EVPI per asylum seeker screened for depression is €4·2 for a €50,000/QALY threshold. 
The total population expected to benefit from perfect information in this intervention is 
estimated at 913,520 over five years. At a threshold of €50,000/QALY, the population EVPI 
is €3·8 million (figure 5). 
 
[insert figure 5] 
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In population EVPPI analyses, eliminating uncertainty around cost and screening 
intervention parameters emerged as being most valuable, at €4·4 million and €3·0 million 
respectively over five years (table 3). Eliminating uncertainty around quality of life gained 
through screening and treatment, screening instrument and treatment effectiveness also 
demonstrated value, at €2·1 million, €1·3 million, and €0·2 million respectively. Parameter 
groups of routine data on regular case-finding and healthcare costs did not emerge as being 
valuable, as the screening intervention remains the dominant option in each iteration of the 
model despite the uncertainty of the parameters in question (table 3). 
4. Discussion 
This modelling study finds that screening for depression can be cost-effective at a 
€50,000/QALY threshold. The probability of the intervention being cost-effective remains 
high (p=83%) once uncertainty of parameters has been considered. Neither the deterministic 
sensitivity analyses nor the structural sensitivity analyses result in an ICER above the 
€50,000/QALY threshold.  
 
Despite the high data scarcity in this area of research, this study has shown that not all 
parameter uncertainty has an equal bearing on results. The cost-effectiveness of the 
intervention is particularly dependent on specific elements of the model. Process parameters 
relating to the screening process, such as the proportion covered by screening, attendance 
rates at diagnostic interviews and therapy, as well as the health outcome utilities and 
psychometric properties of screening tests have a particularly large impact on results.  
 
The overall population EVPI is high at €3·8 million. This reflects both the high probability for 
the cost-effectiveness of screening, the current uncertainty of model parameters and the 
large population of asylum seekers which could benefit from it. The EVPPI demonstrates a 
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high value of €3·0 million to eliminate the uncertainty relating to screening process 
parameters and €4·4 million for more accurate resource requirements and cost estimations, 
as well as considerable value for eliminating uncertainty around health outcome utilities, 
psychometric properties of screening tools and treatment effectiveness. Conducting further 
research on  regular case-finding and healthcare costs did not emerge as valuable, as there 
is enough certainty in these parameters to make a decision between the two alternatives. 
The limited value for further research on these parameters may, however, have been 
affected by uncertainties in the structure of the model, which was not tested in this analysis 
and requires further research. 
 
Analogous to the treatment cascade, the screening cascade which was elicited through this 
study (figure 6) demonstrated a large potential drop-off in individuals who could benefit from 
the intervention at all stages following screening. The advantages of screening individuals 
will be foregone if individuals are lost to follow-up further down the screening cascade. What 
happens following screening, namely the linkage to care, the continued re-engagement with 
patients and the organisation of care, is crucial in ensuring the cost-effectiveness of the 
intervention as a whole. The population of asylum seekers, in Germany and elsewhere, is 
characterised by its heterogeneity [32], meaning that perceptions of how depression should 
be identified and treated may differ substantially between individuals. Thus, experiences and 
expectations of the described process of care are likely to vary markedly, with sensitivities 
around, for example, the gender of the healthcare provider of the setting of the patient-
provider interaction having a large potential impact on adherence to care. Responding to 
these expectations, for example through dedicated case management, is likely to be 
particularly important in keeping individuals engaged with the care process. 
 
[insert figure 6] 
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However, it is precisely these process parameters and the resources required for this 
process which remain largely unexplored in the current literature and which bring the 
greatest degree of uncertainty into the model presented in this paper. The current research 
landscape in this area is heavily focused on the adaptation of screening tools and treatment 
plans for the asylum seeking and refugee population. The present study shows that this 
important work needs to be complemented by studies which embed these tools into models 
of care, with process parameters that allow for an assessment of effectiveness in the entirety 
of the causal chain: screening, referral, treatment and follow-up, as wells a detailed costing 
studies to more accurately depict the resources required for this process. 
 
4.1. Strengths and Limitations 
Given the current scarcity of data, this study can be considered as an explorative, rather 
than definitive, cost-effectiveness analysis, corresponding to Stage II in the iterative 
economic evaluation framework proposed by Sculpher and colleagues [33].  
 
The strength of this analysis lies in the modelling approach, which allows for a synthesis of 
current evidence on the topic of depression screening for asylum seekers and an 
assessment of the sensitivity of results to the uncertainty of parameters. Using economic 
methods, we quantified the value of additional research to further investigate the cost-
effectiveness of the intervention. 
 
The limitations of this analysis lie in the lack of comprehensive data underlying the model. It 
was not possible to build a model representing the natural history of depression, the patient 
journey through a stepped care model, or sub-group differences. In some instances, e.g. for 
the rate of spontaneous remission from depression, reliable and generalisable data for the 
refugee population was not available, and a methodological decision had to be made to 
favour reliable estimates from the general population, at the risk of reduced internal validity. 
It was also not possible to consider a longer timeframe, which may have led to a substantial 
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underestimation of the cost-effectiveness of screening for depression as further benefits are 
likely to accrue beyond the 12 months of follow-up. Further economic analyses could also 
consider the impact on cost-effectiveness of screening for other mental health issues with a 
high relevance for the asylum seeking population (e.g. trauma), either concurrently or 
sequentially to the depression screening. Finally, this model only considers one alternative 
to regular case-finding, although other alternatives, such as dedicated case-finding through 
training & mobilisation of social workers, have been proposed [17].  
 
Furthermore, the lack of reliable data on current demand of asylum seekers for psychosocial 
services in Germany meant that these had to be estimated from the grey literature; the 
resulting comparison arm is simplistic. The treatment parameters used in this model also 
need further consideration, as there is some contention over whether treatments developed 
and tested in a Western context can be assumed to be equally effective for migrants and 
refugees. For the purposes of this project, we draw on the growing body of literature which 
show that the approaches which have been developed to address symptoms of depression 
are suitable for a range of cultural contexts [34].  
 
In addition, the resource estimations made in this model have been informed by studies 
carried out in very different contexts. Additional resource costs, such as start-up costs for a 
screening intervention, costs of social workers who refer to psychosocial centres in the case-
finding scenario and cost incurred from a societal perspective have not been considered 
here. Future studies should apply more rigorous micro-costing approaches, and estimates 
compared with this study. 
 
This study assumes that sufficient resources are available to treat all asylum seekers which 
have screened positive, and that necessary access to care is not restricted. The provision of 
effective and timely treatment is one of the key preconditions of any screening programme 
[35]. However, there is a notorious lack of therapeutic resources currently available for 
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asylum seekers in Germany, and even when capacity is sufficient, most asylum seekers are 
denied treatment on the basis of their residence status [17]. Identifying people in need of 
treatment and subsequently not providing required services is not only inefficient, but also 
unethical. As such, improving the capacity for and granting access to responsive therapeutic 
services is a necessary precondition for a screening intervention.  
 
Not all limitations have an equal bearing on the results of this study. Conservative estimates 
were used in cases where data points were uncertain, so the result of the model is more 
likely to be an underestimation of true cost-effectiveness. Uncertainty around data 
parameters was thoroughly explored in sensitivity analyses; these do not affect the main 
results of the study. More detailed economic models with multiple comparators are required 
to confirm the result of the present study and evaluate the economic rationale for screening 
as more evidence emerges. 
5. Conclusions  
This study presents an explorative model to assess the cost-effectiveness of screening 
asylum seekers for depression when they arrive in Germany. It shows that such an 
intervention has a potential to be cost-effective and that additional research in this field is 
valuable. The resource requirements and acceptability of the screening process, including 
the test and treatment, emerged as particularly important factors in determining the cost-
effectiveness of the intervention. Future research should focus on generating accurate data 
on the process of care following screening, applying more rigorous micro-costing 
approaches to estimate resource requirements along the screening pathway. More accurate 
models with more nuanced representations of the disease progression of depression, 
multiple comparators and a longer time horizon are needed to confirm this result. 
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Figure 3 
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Figure 6: Screening Pathway Cascade of Hypothetical Population-based Screening Intervention 
0
1
2
3
4
5
6
7
8
0
5
0
0
0
1
0
0
0
0
1
5
0
0
0
2
0
0
0
0
2
5
0
0
0
3
0
0
0
0
3
5
0
0
0
4
0
0
0
0
4
5
0
0
0
5
0
0
0
0
5
5
0
0
0
6
0
0
0
0
6
5
0
0
0
7
0
0
0
0
Ex
p
ec
te
d
 V
al
u
e 
(i
n
 m
ill
o
n
 €
)
Cost-effectiveness threshold (€ per QALY )
AC
CE
PT
ED
 M
AN
US
CR
IPT
 27 
 
 
1
0
0
0
9
0
0
3
1
7
1
9
6
1
4
0
7
0
5
6
T O T A L  
C O H O R T
C O V E R E D  B Y  
S C R E E N I N G
D E P R E S S I O N  
S U S P E C T E D
A T T E N D S  
D I A G N O S T I C  
A P P O I N T M E N T
D E P R E S S I O N  
D I A G N O S E D
A C C E P T S  
T H E R A P Y  
O F F E R
T R E A T M E N T  
C O M P L E T E D
AC
CE
PT
ED
 M
AN
US
CR
IPT
 28 
 
 
Table 1: Data Points Used in the Base Case, One-Way Deterministic and Probabilistic Analyses 
Model parameter Mean DSAa 
upper 
DSAa 
lower 
Distribu-
tion 
Standard 
error 
EVPPIa 
group 
Sourceb 
Case-finding pathway 
% identified through case-finding 10·43% 15% 6% uniform - 1 Baron & Flory (2016) 
Screening pathway 
% attending diagnostic interview 62% 87% 37% uniform - 3 Llosa et al.(2017), Bertelsen et al.(2016), Polcher & 
Calloway(2016), Savin et al. (2005) 
% covered by screening 90% 100% 54% uniform - 3 Assumption  
% accepting therapy offer 50% 70% 30% uniform - 3 Polcher & Calloway (2016) 
Depression parameters 
Depression prevalence 30·8% 43% 18% beta 0·023% 1 Steel et al. (2009) 
Spontaneous remission 53% 74% 32% beta 0·033% 5 Whiteford et al. (2013) 
Psychometric properties screening instruments 
Sensitivity PHQ9a 0·813 1 0·49 beta 0·05 2 Mitchell et al. (2016) 
Specificity PHQ9a 0·853 1 0·51 beta 0·02 2 Mitchell et al. (2016) 
Treatment parameters 
Number needed to treat (CBT)a 3·42 4·79 2·05 lognormal 0·31 5 Cuijpers et al. (2013) 
Treatment completion rate 80·3% 100% 48% beta 0·005% 3 Swift & Greenberg (2012) 
% positive outcome among treatment non-completers 20% 28% 12% beta 0·01% 3 Koeser et al. (2015) 
Health-related quality of life 
Healthy (20-29 years old) 0·905 1 0·54 beta 0·002 4 Sullivan et al. (2011) 
Depression in full remission 0·7 0·91 0·42 beta 0·015 4 Kolovos et al. (2017) 
Moderately depressed 0·52 0·73 0·31 beta 0·018 4 Kolovos et al. (2017) 
Resource needs 
Screening: nurse’s time (minutes) 10 14 6 uniform - 6 Valenstein et al. (2001) 
Screening (physician’s time (minutes) 1 1·4 0·6 uniform - 6 Valenstein et al. (2001) 
Length of  clinical appointment (minutes) 90 126 54 uniform - 6 Spitzer at al. (1992) 
Treatment: sessions required 12 16·8 7·2 uniform - 6 Cuijpers et al. (2013) 
Treatment: time per session (minutes) 50 70 30 uniform - 6 Royal College of Psychiatrists (2016) 
Resource costs 
Cost of nurse’s time (per minute) €0·23 €0·33 €0·14 uniform - 6 Öffentlicher Dienst (2017) 
Cost of physician’s time (per minute) €0·42 €0·59 €0·25 uniform - 6 Öffentlicher Dienst (2017) 
Cost of physician contact per quarter €20·45 - - - - - Kassenärztliche Bundesvereinigung (2016) 
Therapeutic costs per 10 minutes €14·19 - - - - - Kassenärztliche Bundesvereinigung (2016) 
Medical coordination costs €20·66 - - - - - Kassenärztliche Bundesvereinigung (2016) 
Translation costs per session €15 €21 €9 uniform - 6 Kassenärztliche Vereinigung Rheinland-Pfalz (2016) 
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aLegend of abbreviations: DSA = Deterministic Sensitivity Analysis; EVPPI = Expected Value of Perfect Parameter Information; PHQ9 = 9-item version of 
Patient Health Questionnaire; CBT = Cognitive Behavioural Therapy 
bAll references for data sources can be found in the supplementary web material (see Additional file 1)
% of patients requiring translation 76% 100% 46% uniform - 6 Baron & Flory (2016) 
Cost of depressed individual (12 months) €209·09 €292·73 €125·45 gamma €83·64 7 Klein-Budde et al. (2013) 
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Table 2: Parameters Used for Structural Deterministic Sensitivity Analyses 
Parameter Value Source 
HADS-Da screening instrument   
Sensitivity 0·72 Brennan et al. (2010) 
Specificity 0·86 Brennan et al. (2010) 
PHQ2a screening instrument   
Sensitivity 0·89 Mitchell et al. (2016) 
Specificity 0·76 Mitchell et al. (2016) 
Screening: nurse’s time (minutes) 8 Assumption  
MINIa diagnostic tool   
Time taken for clinical appointment 
(minutes) 
50 Kassenärztliche 
Bundesvereinigung 
(2016) 
Sensitivity (MINI) 0·94 Lecrubier et al. (1997) 
Specificity (MINI) 0·79 Lecrubier et al. (1997) 
Brief CBTa   
Treatment effectiveness (number needed 
to treat) 
8 Nieuwsma et al. (2012) 
Treatment: sessions required 6 Nieuwsma et al. (2012) 
Treatment: time per session (minutes) 30 Nieuwsma et al. (2012) 
 
aLegend of abbreviations: HADS-D = Hospital Anxiety and Depressions Scale; PHQ2 = 2-item version of the Patient 
Health Questionnaire; MINI = Mini International Neuropsychiatric Interview; CBT = Cognitive Behavioural Therapy 
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Table 3: Parameter Groups Used for and Outcome of Expected Value of Perfect Parameter Information 
Analysis 
 Group Parameters included EVPPI 
1 Routine data  % identified through case-finding  
Depression prevalence 
€ 0 
2 Screening instrument properties Sensitivity PHQ9 
Specificity PHQ9 €1,261,431 
3 Screening intervention parameters % attending diagnostic interview 
% accepting therapy offer 
% completing treatment 
% covered by screening 
% positive outcome among treatment 
non-completers €3,042,937  
4 Utility values Healthy (20-29 years old) health utility 
Depression in full remission health 
utility 
Moderately depressed health utility €2,113,743 
5 Treatment effectiveness Spontaneous remission 
Number needed to treat (CBT) €194,018 
6 Service costs Screening: nurse’s time (minutes) 
Screening: physician’s time (minutes) 
Time required for clinical appointment 
(minutes) 
Treatment: sessions required 
Treatment: time per session (minutes) 
Cost of nurse’s time (per minute) 
Cost of physician’s time (per minute) 
Translation costs per session 
% of patients requiring translation €4,360,283 
7 Healthcare costs Cost of depressed health outcome €0 
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Table 4: Results of Base Case, Scenario and Structural Uncertainty Analyses 
Analysis QALYs Cost ICER 
Base case results 
Do Nothing 801·11 €47,334 - 
Case-finding 803·63 €78,982 - 
Screening 806·58 €137,398 - 
Case-finding vs. Do Nothing  2·51 €31,648 €12,588 
Screening vs. Case-finding  2·95 €58,416 €19,779 
Scenario and structural uncertainty analyses (incremental results) 
HADS-Da screening tool vs. Case-finding 2·33 €48,959 €21,030 
PHQ2a screening tool vs. Case-finding 3·47 €70,817 €20,401 
Brief CBTa therapy vs. Case-finding 2·04 €36,874 €18,073 
MINIa diagnostic tool vs. Case-finding 1·89 €51,483 €27,263 
 
aLegend of abbreviations: HADS-D = Hospital Anxiety and Depressions Scale; PHQ2 = 2-item version of the Patient 
Health Questionnaire; CBT = Cognitive Behavioural Therapy; MINI = Mini International Neuropsychiatric Interview
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Additional files 
 
File name:  Additional_file_1.docx 
Title of data: Web Appendix - Additional Details on Methodology and Data Sources 
Caption: Additional methodological details required to replicate the economic model presented as well 
as a full list of references for data sources. 
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